The ability to manipulate the development and function of Bglap+ osteogenic cells and local osteoclastogenesis by modulating SHP2 activity suggests a new strategy to combat OB-related disorders, such as osteoporosis. The gene discussed is BGLAP; the disease is osteoporosis.